Cyclic nucleotide-gated channel subunit beta 3 (CNGB3) (CNGB3)

Cyclic nucleotide-gated channel subunit beta 3 (CNGB3) is a critical protein component of the ion channels located in the outer segments of cone photoreceptor cells in the retina (UniProt Q9NQW8). These channels are essential for the phototransduction cascade, where they convert light-induced changes in cyclic GMP (cGMP) levels into electrical signals that the brain processes as visual information (NCBI Gene 54714). Mutations in the CNGB3 gene are the most common cause of achromatopsia, a rare genetic disorder characterized by a complete lack of color vision, extreme light sensitivity, and significantly reduced visual acuity (OMIM 605080). Because the disease results from a loss of functional protein, CNGB3 is a primary target for gene replacement therapies using adeno-associated virus (AAV) vectors. Several investigational therapies, such as AGTC-401 and larupretigene zosaparvovec, are currently in clinical trials aiming to deliver a functional copy of the gene to the subretinal space to restore cone function (ClinicalTrials.gov NCT02599922). Successful treatment relies on the presence of viable cone cells, which are monitored using biomarkers like optical coherence tomography and electroretinography.

Other names

Cyclic nucleotide-gated channel beta-3CNG channel beta-3ACHM3CCNCBLCNG3Cone photoreceptor cGMP-gated cation channel beta-subunit

Gene replacement therapy via viral vector delivery to restore functional cyclic nucleotide-gated channels in cone photoreceptors.